8-K: Karyopharm Submits sNDA for XPOVIO in Myelofibrosis

Karyopharm Therapeutics has submitted a supplemental New Drug Application (sNDA) to the FDA for XPOVIO in combination with ruxolitinib for myelofibrosis patients, seeking Accelerated Approval.

Summary

• Karyopharm Therapeutics Inc. announced on August 31, 2026, that it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA).
• The sNDA seeks Accelerated Approval for XPOVIO (selinexor) when used in combination with ruxolitinib for patients diagnosed with myelofibrosis.
• The company has requested Priority Review for this application, which could shorten the FDA's review process to six months if granted.
• Karyopharm anticipates receiving notification from the FDA regarding the sNDA's filing acceptance and review timelines in the fourth quarter of 2026.
• The submission is supported by data from the Phase 3 SENTRY trial, which the company believes demonstrates a favorable benefit-risk profile, including a promising overall survival signal.
• Accelerated Approval is anticipated if the FDA agrees that a 35% spleen volume reduction (SVR35) is a reliable predictor of overall survival.
• The company plans to utilize long-term overall survival data from the SENTRY trial to confirm clinical benefit and transition from accelerated to traditional approval.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, driven by a significant regulatory submission with potential for accelerated approval, though contingent on FDA review and future data.

Positives

• Submission of an sNDA to the FDA for XPOVIO in combination with ruxolitinib for myelofibrosis.
• Seeking Accelerated Approval, which could expedite market access.
• Request for Priority Review, potentially reducing the review timeline to six months.
• Data from the Phase 3 SENTRY trial supports a positive benefit-risk profile, including a promising overall survival signal.
• Productive engagement with the FDA following topline results of the SENTRY trial.

Negatives

• Approval is contingent on the FDA's assessment of spleen volume reduction (SVR35) as a surrogate endpoint for overall survival.
• The company faces the ongoing risk of not obtaining regulatory approval or facing delays in the review process.
• Substantial doubt exists regarding the Company's ability to continue as a going concern, as noted in previous filings.

Risks

• The FDA may not agree that SVR35 is a reasonably likely surrogate endpoint to predict overall survival.
• There is no guarantee that the sNDA will be accepted for review or that it will ultimately receive approval.
• The company may not be able to successfully convert accelerated approval to traditional approval with long-term overall survival data.
• Competitors may develop or gain approval for alternative treatments for myelofibrosis.
• The company's ability to enroll patients in ongoing clinical trials could be impacted.
• Unplanned cash requirements and expenditures could arise.
• Risks related to the adoption of XPOVIO in the commercial marketplace.
• Uncertainty regarding the timing and costs involved in commercializing XPOVIO or other drug candidates.

Future Outlook

The company expects to receive notice of the FDA's decision on the sNDA filing acceptance and review timelines in the fourth quarter of 2026. Karyopharm plans to use long-term overall survival data from the Phase 3 SENTRY trial to verify clinical benefit and support conversion from accelerated to traditional approval.

Management Comments

• The sNDA submitted is based, in part, on data from the SENTRY trial that the Company believes supports a positive benefit-risk profile for the combination, including a promising signal of overall survival.
• The Company expects approval under the Accelerated Approval pathway would require the FDA to agree that spleen volume reduction 35% (SVR35) is a reasonably likely surrogate endpoint to predict overall survival.
• The Company plans to use long-term overall survival data from the Phase 3 SENTRY trial to verify clinical benefit and support conversion from accelerated to traditional approval and expects to continue working with the FDA during its review of the sNDA to finalize the confirmatory evidence plan.

Industry Context

StockSavvy.ai notes that the submission of an sNDA for Accelerated Approval in myelofibrosis reflects the ongoing efforts within the oncology sector to leverage novel drug combinations and expedited regulatory pathways to address unmet medical needs. The focus on SVR35 as a surrogate endpoint is a common strategy in hematology-oncology, aiming to bring potentially life-extending therapies to patients faster.

Stakeholder Impact

• Shareholders: Potential positive impact if the sNDA is approved, leading to increased revenue and market share. However, the 'going concern' note from previous filings remains a significant risk.
• Patients: Potential for earlier access to a new treatment option for myelofibrosis if Accelerated Approval is granted.
• FDA: The agency will conduct a thorough review of the submitted data to determine the drug's safety and efficacy.
• Healthcare Providers: Will evaluate the clinical data to determine the utility of XPOVIO in combination with ruxolitinib for their patients.

Next Steps

• Receive FDA's decision on sNDA filing acceptance and review timelines in Q4 2026.
• Continue working with the FDA during the sNDA review to finalize the confirmatory evidence plan.
• Utilize long-term overall survival data from the Phase 3 SENTRY trial to verify clinical benefit and support conversion to traditional approval.

Key Dates

Recommendation

The filing presents a significant regulatory step with potential for accelerated approval, which is positive. However, the outcome is still subject to FDA review, and the company's ongoing 'going concern' status from previous filings introduces substantial risk. Therefore, a 'hold' recommendation is appropriate pending further clarity on regulatory decisions and the company's financial stability.

Keywords

myelofibrosis, XPOVIO, selinexor, ruxolitinib, sNDA, FDA, Accelerated Approval, Priority Review